| Not Yet Recruiting | Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC NCT07339839 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Not Yet Recruiting | Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With NCT07298148 | Peking University Cancer Hospital & Institute | Phase 2 |
| Recruiting | ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants NCT06745908 | ImmunityBio, Inc. | Phase 3 |
| Recruiting | TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% NCT07279402 | Antalya Training and Research Hospital | — |
| Recruiting | Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases NCT06401824 | Maastricht University Medical Center | Phase 2 |
| Recruiting | Outpatient Pulmonary Rehabilitation in Non-small-cell Lung Cancer Receiving Immunotherapy NCT06436625 | Karl Landsteiner Institute for Lung Research and Pneumological Oncology | N/A |
| Recruiting | Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC NCT06219317 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Not Yet Recruiting | A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) NCT05859217 | Jun Zhang, MD, PhD | Phase 2 |
| Not Yet Recruiting | HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ N NCT06218940 | Newsoara Biopharma Co., Ltd. | Phase 1 |
| Recruiting | Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC NCT06552234 | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | Phase 2 |
| Not Yet Recruiting | Cancer Patient Remote Monitoring for Timely Communication Study NCT06623786 | Asklepios proresearch | — |
| Recruiting | Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer NCT06523673 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 3 |
| Recruiting | ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer NCT06532149 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Met NCT06501378 | Fudan University | Phase 2 |
| Recruiting | Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Met NCT06501391 | Fudan University | Phase 2 |
| Recruiting | Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC NCT05950139 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Not Yet Recruiting | Exercise in Patients With Advanced Non-small Cell Lung Cancer NCT06374160 | University Hospital, Essen | N/A |
| Recruiting | Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line I NCT06313541 | Fudan University | Phase 2 |
| Recruiting | AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer NCT06788366 | IRCCS San Raffaele | — |
| Recruiting | A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cance NCT06512207 | Jinzhou Medical University | N/A |
| Active Not Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combi NCT05787613 | Shanghai Henlius Biotech | Phase 2 |
| Active Not Recruiting | Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status NCT05673187 | ETOP IBCSG Partners Foundation | Phase 2 |
| Withdrawn | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC NCT05212922 | Eucure (Beijing) Biopharma Co., Ltd | Phase 2 |
| Terminated | A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197 | Lyell Immunopharma, Inc. | — |
| Terminated | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer NCT05652868 | Mythic Therapeutics | Phase 1 |
| Active Not Recruiting | Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) NCT05816499 | Shanghai Chest Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid NCT05597800 | Universita di Verona | Phase 2 |
| Terminated | Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC NCT05691829 | NYU Langone Health | Phase 2 |
| Recruiting | A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) NCT05657873 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC NCT05543330 | Wuhan YZY Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer NCT05533086 | Xiaohua Zhu | — |
| Recruiting | Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Canc NCT05344209 | Vestre Viken Hospital Trust | Phase 2 |
| Terminated | Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC NCT04908956 | ETOP IBCSG Partners Foundation | Phase 2 |
| Recruiting | Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC NCT05332925 | Jun Zhang, MD, PhD | — |
| Completed | Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma NCT05303493 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 1 |
| Completed | A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) NCT05429320 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities NCT05311709 | Vestre Viken Hospital Trust | Phase 2 |
| Withdrawn | Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus P NCT05383001 | AIO-Studien-gGmbH | Phase 2 |
| Recruiting | Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC NCT04467723 | University of Kansas Medical Center | Phase 1 / Phase 2 |
| Unknown | SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors NCT05387044 | Zhejiang Cancer Hospital | Phase 2 |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Recruiting | Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCL NCT04136535 | Fudan University | Phase 2 |
| Recruiting | Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After S NCT05281406 | Goethe University | Phase 2 |
| Unknown | Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer NCT05132218 | Peking University Cancer Hospital & Institute | — |
| Active Not Recruiting | Primary Tumor Resection With EGFR TKI for Stage IV NSCLC NCT05215548 | National Taiwan University Hospital | Phase 2 |
| Unknown | Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy NCT04467801 | Jun Zhang, MD, PhD | Phase 2 |
| Unknown | Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSC NCT05055583 | Tang-Du Hospital | Phase 2 |
| Recruiting | Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project) NCT06234579 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Unknown | Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor NCT04932343 | Samsung Medical Center | — |
| Completed | SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs NCT04764214 | Fudan University | Phase 2 |
| Completed | AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) NCT04364620 | Alethia Biotherapeutics | Phase 2 |
| Terminated | Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Witho NCT04676386 | Addario Lung Cancer Medical Institute | — |
| Recruiting | SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors NCT04767009 | Fudan University | Phase 2 |
| Unknown | Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemo NCT04613804 | Fujian Cancer Hospital | Phase 2 |
| Completed | Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC NCT04507906 | Shanghai Chest Hospital | Phase 1 / Phase 2 |
| Unknown | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inope NCT04521075 | Ella Therapeutics Ltd | Phase 1 / Phase 2 |
| Unknown | Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2 NCT04604470 | Maastricht University | — |
| Terminated | Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC NCT04549428 | Oncology Institute of Southern Switzerland | Phase 2 |
| Completed | Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC NCT04507217 | Sun Yat-sen University | Phase 2 |
| Unknown | Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSC NCT04768491 | Peking Union Medical College | — |
| Unknown | Prospective Observation of Failure Patterns in NSCLC Treated With ICIs NCT04492969 | Fudan University | — |
| Recruiting | Lung Cancer Registry NCT04654364 | Arbeitsgemeinschaft medikamentoese Tumortherapie | — |
| Unknown | Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) NCT04636775 | Jun Zhang, MD, PhD | — |
| Active Not Recruiting | Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients NCT04223596 | Fundación GECP | Phase 2 |
| Unknown | PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC NCT04284202 | The Affiliated Hospital of Qingdao University | Phase 2 |
| Active Not Recruiting | Plasma-Adapted First-Line Pembro In NSCLC NCT04166487 | Julia K. Rotow, MD | Phase 2 |
| Unknown | Camrelizumab Combined With Local Treatment in NSCLC Patients With BM NCT04291092 | Zhejiang Cancer Hospital | Phase 2 |
| Unknown | SRS Sequential Sindilimab in Brain Metastasis of NSLSC NCT04180501 | Xiaorong Dong | Phase 2 |
| Unknown | Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Canc NCT04102982 | Shandong Provincial Hospital | Phase 2 |
| Unknown | SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC NCT04106180 | Fudan University | Phase 2 |
| Completed | A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squam NCT04042558 | Centre Francois Baclesse | Phase 2 |
| Active Not Recruiting | Phase 2 Study of Dacomitinib in NSCLC NCT04027647 | National Cancer Centre, Singapore | Phase 2 |
| Unknown | Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC NCT04116918 | Baodong Qin | — |
| Terminated | Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in NCT03777124 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Terminated | IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study NCT03705403 | Maastricht University Medical Center | Phase 2 |
| Terminated | FGFR Inhibitor in FGFR Dysregulated Cancer NCT03827850 | Lung Cancer Group Cologne | Phase 2 |
| Terminated | Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumo NCT03805841 | Rain Oncology Inc | Phase 2 |
| Active Not Recruiting | Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Ca NCT03808662 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations NCT05701787 | Shanghai Chest Hospital | — |
| Active Not Recruiting | 1st Line Durvalumab in PS 2 NSCLC Patients NCT03620669 | Swiss Cancer Institute | Phase 2 |
| Terminated | Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patient NCT03713944 | Nasser Hanna | Phase 2 |
| Completed | 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC NCT03564197 | The Netherlands Cancer Institute | N/A |
| Completed | Alectinib-induced Endocrine Toxicity NCT06339554 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Unknown | Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Pati NCT03647956 | The University of Hong Kong | Phase 2 |
| Unknown | Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A NCT03594682 | Beijing Chest Hospital | N/A |
| Completed | T790M Mutation Testing in Blood by Different Methodologies NCT03363139 | Spanish Lung Cancer Group | — |
| Unknown | The Role of Microbiota on the Development of Lung Cancer NCT03454685 | Xiaorong Dong | — |
| Terminated | Early Response Evaluation in NSCLC Patients Treated With Immunotherapy NCT04082988 | The Netherlands Cancer Institute | N/A |
| Unknown | Factors Determining the Prognosis in NSCLC Stage IV NCT04306094 | Instituto do Cancer do Estado de São Paulo | — |
| Terminated | Study of AGEN1884 With Pembrolizumab in 1L NSCLC NCT03411473 | Agenus Inc. | Phase 2 |
| Completed | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (N NCT03184571 | BerGenBio ASA | Phase 2 |
| Unknown | Neo-MASCT Immunotherapy for Advanced NSCLC. NCT03205930 | The First People's Hospital of Lianyungang | Phase 1 / Phase 2 |
| Withdrawn | Phase I Study of SPH1188-11 in NSCLC NCT03231475 | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 |
| Withdrawn | To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NCT03130829 | Hi-Q Marine Biotech International, Ltd. | N/A |
| Completed | Cachexia in NSCLC Patients: Diagnosis, Characterization, Prognosis, Functional and Skeletal Muscle Implication NCT03960034 | Instituto do Cancer do Estado de São Paulo | — |
| Unknown | EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide NCT03341494 | Fujian Cancer Hospital | Phase 2 |
| Completed | MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC NCT04633564 | Mylan Pharmaceuticals Inc | Phase 3 |
| Completed | Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients NCT04076228 | Kiang Wu Hospital | — |
| Unknown | Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer NCT06207292 | Radiotherapy Oncology Centre "Santa Maria" Hospital | N/A |
| Completed | Donation of Post Mortem Tumor Tissues NCT03385980 | Niguarda Hospital | — |
| Withdrawn | Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR) NCT02735850 | Maastricht Radiation Oncology | Phase 2 |
| Completed | Genomic Study in Non-small Cell Lung Cancer Brain Metastasis NCT04745715 | National Cheng-Kung University Hospital | — |
| Completed | Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer NCT03515252 | Ivy Life Sciences, Co., Ltd | Phase 1 |